Author name: DrugChatter

Spend enough time watching patient questions, and a pattern emerges: people aren’t just asking what works—they’re asking what they can […]

Scroll through enough patient questions and a pattern emerges: people aren’t just taking drugs—they’re tuning them. Combining, stretching, substituting. Off-label

If you want to understand how patients actually think about switching between similar drugs, don’t look for clean “Drug A

Physicians are increasingly asking AI chatbots how to dose drugs, manage contraindications, and choose between therapies. The AI answers. The

The pharmaceutical industry has spent decades building brand reputations through clinical trials, physician detailing, and tightly controlled messaging. That infrastructure

If you want to know when adherence breaks, don’t look at refill data. That’s the autopsy. The early signals show

Why Pharmaceutical Brands Must Shift from Social Listening to AI Monitoring — Before Regulators Do The clinical detail rep used

How large language models are quietly reshaping brand exposure, regulatory liability, and the future of pharmacovigilance The alert came from

How pharmaceutical brands are losing control of patient conversations, clinical narratives, and competitive positioning inside the black box of generative

How pharmaceutical companies are using AI surveillance tools to protect brand integrity, stay ahead of the FDA, and decode what

Walk into any pharmaceutical brand team meeting in 2025 and you’ll hear the same anxieties: biosimilar erosion, payer step therapy,

The pharmacovigilance team at a mid-size specialty pharma company discovered the problem during a routine brand audit. Patients searching for